Hydromethylthionine mesylate is under clinical development by TauRx Pharmaceuticals and currently in Phase III for Mild Cognitive Impairment. According to GlobalData, Phase III drugs for Mild Cognitive Impairment does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Hydromethylthionine mesylate LoA Report. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hydromethylthionine mesylate overview
Hydromethylthionine mesylate (LMTX) is under development for the treatment of Alzheimer’s disease (AD), mild cognitive impairment, Parkinson’s disease and frontotemporal lobar degeneration syndromes (FTLD) including progressive supranuclear palsy and corticobasal degeneration syndrome. It is a small molecule administered orally. The drug candidate is a leuco-methylthioninium, a new chemical entity and a second-generation Tau aggregation inhibitor (TAI). It also acts on TDP-43 protein. It is based on proprietary drug discovery platform. It was also under development for the treatment of progressive non-fluent aphasia and behavioural-variant frontotemporal dementia (FTD-Pick’s Disease).
TauRx Pharmaceuticals overview
TauRx Pharmaceuticals (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases. The company discovers, assesses and develops new compounds and biologics with therapeutic and diagnostic for neurodegenerative diseases caused by protein aggregation. Its lead product hydromethylthionine mesylate (HMTM), which is intended for the treatment of Alzheimer’s and related diseases. The company’s therapeutic areas include neurodegenerative disorders, mild cognitive impairment, Alzheimer’s disease and frontotemporal dementia. It undertakes clinical trials for several drugs and works in partnership with academic institutions and other pharmaceutical companies active in the field of neurodegeneration. TauRx is headquartered in Singapore City, Singapore.
For a complete picture of Hydromethylthionine mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
